Frances A Lemckert1, Adam Bournazos2, Daniel M Eckert2, Manuel Kenzler2, Joanne M Hawkes3, Tanya L Butler3, Bradley Ceely4, Kathryn N North5, David S Winlaw4, Jonathan R Egan4, Sandra T Cooper5. 1. Institute for Neuroscience and Muscle Research, Kids Research Institute, The Children's Hospital at Westmead, Locked Bag 4001, Westmead 2145, Australia frances.lemckert@sydney.edu.au. 2. Institute for Neuroscience and Muscle Research, Kids Research Institute, The Children's Hospital at Westmead, Locked Bag 4001, Westmead 2145, Australia. 3. Kid's Hearts Research, Heart Centre for Children, The Children's Hospital at Westmead, Westmead 2145, Australia. 4. Kid's Hearts Research, Heart Centre for Children, The Children's Hospital at Westmead, Westmead 2145, Australia Discipline of Paediatrics and Child Health, University of Sydney, Children's Hospital at Westmead Clinical School, Westmead 2145, Australia. 5. Institute for Neuroscience and Muscle Research, Kids Research Institute, The Children's Hospital at Westmead, Locked Bag 4001, Westmead 2145, Australia Discipline of Paediatrics and Child Health, University of Sydney, Children's Hospital at Westmead Clinical School, Westmead 2145, Australia.
Abstract
AIMS: Mitsugumin-53 (MG53/TRIM72) is an E3-ubiquitin ligase that rapidly accumulates at sites of membrane injury and plays an important role in membrane repair of skeletal and cardiac muscle. MG53 has been implicated in cardiac ischaemia-reperfusion injury, and serum MG53 provides a biomarker of skeletal muscle injury in the mdx mouse model of Duchenne muscular dystrophy. We evaluated the clinical utility of MG53 as a biomarker of myocardial injury. METHODS AND RESULTS: We performed Langendorff ischaemia-reperfusion injury on wild-type and dysferlin-null murine hearts, using dysferlin deficiency to effectively model more severe outcomes from cardiac ischaemia-reperfusion injury. MG53 released into the coronary effluent correlated strongly and significantly (r = 0.79-0.85, P < 0.0001) with functional impairment after ischaemic injury. We initiated a clinical trial in paediatric patients undergoing corrective heart surgery, the first study of MG53 release with myocardial injury in humans. Unexpectedly, we reveal although MG53 is robustly expressed in rat and mouse hearts, MG53 is scant to absent in human, ovine, or porcine hearts. Absence of MG53 in 11 human heart specimens was confirmed using three separate antibodies to MG53, each subject to epitope mapping and confirmed immunospecificity using MG53-deficient muscle cells. CONCLUSION: MG53 is an effective biomarker of myocardial injury and dysfunction in murine hearts. However, MG53 is not expressed in human heart and therefore does not hold utility as a clinical biomarker of myocardial injury. Although cardioprotective roles for endogenous myocardial MG53 cannot be extrapolated from rodents to humans, potential therapeutic application of recombinant MG53 for myocardial membrane injury prevails. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Mitsugumin-53 (MG53/TRIM72) is an E3-ubiquitin ligase that rapidly accumulates at sites of membrane injury and plays an important role in membrane repair of skeletal and cardiac muscle. MG53 has been implicated in cardiac ischaemia-reperfusion injury, and serum MG53 provides a biomarker of skeletal muscle injury in the mdx mouse model of Duchenne muscular dystrophy. We evaluated the clinical utility of MG53 as a biomarker of myocardial injury. METHODS AND RESULTS: We performed Langendorff ischaemia-reperfusion injury on wild-type and dysferlin-null murine hearts, using dysferlin deficiency to effectively model more severe outcomes from cardiac ischaemia-reperfusion injury. MG53 released into the coronary effluent correlated strongly and significantly (r = 0.79-0.85, P < 0.0001) with functional impairment after ischaemic injury. We initiated a clinical trial in paediatric patients undergoing corrective heart surgery, the first study of MG53 release with myocardial injury in humans. Unexpectedly, we reveal although MG53 is robustly expressed in rat and mouse hearts, MG53 is scant to absent in human, ovine, or porcine hearts. Absence of MG53 in 11 human heart specimens was confirmed using three separate antibodies to MG53, each subject to epitope mapping and confirmed immunospecificity using MG53-deficient muscle cells. CONCLUSION:MG53 is an effective biomarker of myocardial injury and dysfunction in murine hearts. However, MG53 is not expressed in human heart and therefore does not hold utility as a clinical biomarker of myocardial injury. Although cardioprotective roles for endogenous myocardial MG53 cannot be extrapolated from rodents to humans, potential therapeutic application of recombinant MG53 for myocardial membrane injury prevails. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang Journal: Nat Protoc Date: 2013-10-24 Impact factor: 13.491
Authors: Angela Lek; Frances J Evesson; Frances A Lemckert; Gregory M I Redpath; Ann-Katrin Lueders; Lynne Turnbull; Cynthia B Whitchurch; Kathryn N North; Sandra T Cooper Journal: J Neurosci Date: 2013-03-20 Impact factor: 6.167
Authors: Huei-Ping Tzeng; Sarah Evans; Feng Gao; Kari Chambers; Veli K Topkara; Natarajan Sivasubramanian; Philip M Barger; Douglas L Mann Journal: J Am Heart Assoc Date: 2014-02-26 Impact factor: 5.501
Authors: Kevin E McElhanon; Nicholas Young; Jeffrey Hampton; Brian J Paleo; Thomas A Kwiatkowski; Eric X Beck; Ana Capati; Kyle Jablonski; Travis Gurney; Miguel A Lopez Perez; Rohit Aggarwal; Chester V Oddis; Wael N Jarjour; Noah Weisleder Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: Yasuhiro Ichikawa; Alice E Zemljic-Harpf; Zheng Zhang; M Dan McKirnan; Ana Maria Manso; Robert S Ross; H Kirk Hammond; Hemal H Patel; David M Roth Journal: PLoS One Date: 2017-05-12 Impact factor: 3.240